Page last updated: 2024-12-11
cg100649
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
CG100649: a cyclooxygenase-2 inhibitor with both anti-inflammatory and antineoplastic activities; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9841854 |
CHEMBL ID | 166863 |
SCHEMBL ID | 3233093 |
MeSH ID | M000607620 |
Synonyms (43)
Synonym |
---|
cg100649 |
polmacoxib |
CHEMBL166863 |
cg-100649 |
polmacoxib [usan] |
1427301-99-2 |
polmacoxib [inn] |
4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl]-benzenesulfonamide |
polmacoxib [who-dd] |
benzenesulfonamide, 4-(3-(3-fluorophenyl)-4,5-dihydro-5,5-dimethyl-4-oxo-2-furanyl)- |
polmacoxib [usan:inn] |
cg 100649 |
unii-ij34d6ypao |
301692-76-2 |
4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-benzenesulfonamide |
ij34d6ypao , |
IJWPAFMIFNSIGD-UHFFFAOYSA-N |
5-{4-(aminosulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2h)-furanone |
SCHEMBL3233093 |
polmacoxib (usan/inn) |
D10656 |
AKOS025149767 |
acelex (s. korea) |
4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxofuran-2-yl]benzenesulfonamide |
gtpl8316 |
J-690277 |
2-(4-tert-butylphenyl)-1h-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1h-benzimidazole |
4-[3-(3-fluorophenyl)-5,5-dimethyl-4-oxidanylidene-furan-2-yl]benzenesulfonamide |
EX-A601 |
bdbm50474760 |
4-(3-(3-fluorophenyl)-5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)benzenesulfonamide |
DB12399 |
BCP15550 |
cg100649; cg-100649; cg 100649 |
FT-0700281 |
Q19598695 |
SB17177 |
A857030 |
MS-25723 |
polmacoxibcg100649 |
DTXSID901029389 |
CS-0012326 |
HY-16726 |
Research Excerpts
Overview
CG100649 is a novel anti-inflammatory drug that is currently under development. It is a new member of the COXIB family, which is proposed to inhibit both COX-2 and carbonic anhydrase (CA) activity.
Toxicity
Pharmacokinetics
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | IC50 (µMol) | 0.0030 | 0.0007 | 2.0844 | 5.1000 | AID1532180 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Bioassays (9)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID234556 | Selectivity against COX-2 over COX-1 | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4 | In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. |
AID183650 | Inhibition of carrageenan-induced rat foot oedema following 3 mg/kg administration. | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4 | In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. |
AID160565 | In vitro inhibitory activity against prostaglandin G/H synthase 2 using mouse peritoneal macrophage method | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4 | In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. |
AID1532180 | Inhibition of COX-1 in LPS-induced mouse peritoneal macrophages | 2019 | European journal of medicinal chemistry, Jan-15, Volume: 162 | Medicinal chemistry of vicinal diaryl scaffold: A mini review. |
AID178664 | Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using preventive method; dose administered daily twice | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4 | In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. |
AID161996 | In vitro inhibitory activity against prostaglandin G/H synthase 1 using mouse peritoneal macrophage method | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4 | In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. |
AID178667 | Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using therapeutic method; dose administered daily twice | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4 | In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. |
AID178666 | Antiinflammatory activity was determined by measuring adjuvant-induced arthritis in rats using therapeutic method; dose administered daily once | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4 | In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. |
AID168048 | Ability of compound to cause gastric ulcerogenicity was determined in rats at 5 mg/kg | 2004 | Journal of medicinal chemistry, Feb-12, Volume: 47, Issue:4 | In vitro structure-activity relationship and in vivo studies for a novel class of cyclooxygenase-2 inhibitors: 5-aryl-2,2-dialkyl-4-phenyl-3(2H)furanone derivatives. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 8 (80.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.84
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 3 (27.27%) | 5.53% |
Reviews | 2 (18.18%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (54.55%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |